SAN DIEGO, Sept. 18, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the UBS Global Life Sciences Conference on September 23, 2009 at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Jack Lief, Arena''s President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.
A live audio webcast of the presentation will be available under the investor relations section of Arena''s website at http://www.arenapharm.com/. A replay of the presentation will be available for 30 days following the event. Please connect to Arena''s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena''s most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena has a broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, which includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Arena Pharmaceuticals and Arena are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena''s strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena''s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena''s lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena''s ability to partner or commercialize lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena''s ability to obtain additional funds; Arena''s ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena''s collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena''s forward-looking statements are disclosed in Arena''s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena''s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contact: Arena Pharmaceuticals, Inc. Jack Lief President and Chief Executive Officer Cindy McGee Manager, Investor Relations and Corporate Communications 858.453.7200, ext. 1479 Media Contact: Russo Partners David Schull, President david.schull@russopartnersllc.com 212.845.4271
Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and Chief Executive Officer, or Cindy
McGee, Manager, Investor Relations and Corporate Communications,
+1-858-453-7200, ext. 1479, both of Arena Pharmaceuticals, Inc., Media, David
Schull, President of Russo Partners, +1-212-845-4271,
david.schull@russopartnersllc.com, for Arena Pharmaceuticals, Inc.
Web Site: http://www.arenapharm.com/
